Stuart M Flechner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6306259/publications.pdf

Version: 2024-02-01

117453 118652 3,973 107 34 62 citations g-index h-index papers 108 108 108 3455 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1. Transplantation, 2002, 74, 1070-1076.	0.5	353
2	De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at Two Years. American Journal of Transplantation, 2004, 4, 1776-1785.	2.6	270
3	Kidney Transplant Rejection and Tissue Injury by Gene Profiling of Biopsies and Peripheral Blood Lymphocytes. American Journal of Transplantation, 2004, 4, 1475-1489.	2.6	264
4	The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients. American Journal of Transplantation, 2011, 11, 1633-1644.	2.6	194
5	Kidney Transplantation With Sirolimus and Mycophenolate Mofetil–Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs. Transplantation, 2007, 83, 883-892.	0.5	138
6	Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clinical Transplantation, 2007, 22, 070618134134002-???.	0.8	136
7	SHOULD OBESE PATIENTS LOSE WEIGHT BEFORE RECEIVING A KIDNEY TRANSPLANT?. Transplantation, 1997, 64, 599-604.	0.5	134
8	The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation, 2003, 76, 1729-1734.	0.5	132
9	A RANDOMIZED PROSPECTIVE CONTROLLED TRIAL OF ORAL ACYCLOVIR VERSUS ORAL GANCICLOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS1. Transplantation, 1998, 66, 1682-1688.	0.5	118
10	DETERMINANTS OF CHRONIC RENAL ALLOGRAFT REJECTION IN CYCLOSPORINE-TREATED RECIPIENTS. Transplantation, 1996, 62, 1235-1241.	0.5	102
11	The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation. Transplantation, 2010, 90, 1486-1492.	0.5	97
12	The Influence of Various Maintenance Immunosuppressive Drugs on Lymphocele Formation and Treatment After Kidney Transplantation. Journal of Urology, 2004, 171, 1788-1792.	0.2	84
13	mTOR inhibitorâ€associated dermatologic and mucosal problems. Clinical Transplantation, 2010, 24, 149-156.	0.8	80
14	Association between Kidney Transplant Center Performance and the Survival Benefit of Transplantation Versus Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1773-1780.	2.2	79
15	TRANSPLANTATION OF PEDIATRIC EN BLOC CADAVER KIDNEYS INTO ADULT RECIPIENTS1. Transplantation, 1998, 66, 1689-1694.	0.5	78
16	Transplantation into the Long-term Defunctionalized Bladder. Journal of Urology, 1996, 156, 885-888.	0.2	75
17	Biomarkers for Early and Late Stage Chronic Allograft Nephropathy by Proteogenomic Profiling of Peripheral Blood. PLoS ONE, 2009, 4, e6212.	1.1	74
18	A Systematic Approach to Minimizing Wound Problems for De Novo Sirolimus-Treated Kidney Transplant Recipients. Transplantation, 2009, 87, 296-302.	0.5	72

#	Article	IF	Citations
19	The first 9 years of kidney paired donation through the National Kidney Registry: Characteristics of donors and recipients compared with National Live Donor Transplant Registries. American Journal of Transplantation, 2018, 18, 2730-2738.	2.6	70
20	Posttransplant Diabetes Mellitus in Kidney Transplant Recipients Receiving Calcineurin or mTOR Inhibitor Drugs. Transplantation, 2006, 81, 335-341.	0.5	68
21	Transient versus Persistent BK Viremia and Long-Term Outcomes after Kidney and Kidney–Pancreas Transplantation. Clinical Journal of the American Society of Nephrology: CJAŚN, 2014, 9, 553-561.	2.2	67
22	Differences in Proteinuria and Graft Function in De Novo Sirolimus-Based vs. Calcineurin Inhibitor-Based Immunosuppression in Live Donor Kidney Transplantation. Transplantation, 2006, 82, 368-374.	0.5	66
23	Management of the Adrenal Gland During Partial Nephrectomy. Journal of Urology, 2009, 181, 2430-2437.	0.2	60
24	An Emerging Population. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1881-1886.	2.2	59
25	Expression of IL-8 during Reperfusion of Renal Allografts Is Dependent on Ischemic Time. Transplantation, 2006, 81, 783-788.	0.5	57
26	Sirolimus in Kidney Transplantation Indications and Practical Guidelines: De novo Sirolimus-Based Therapy Without Calcineurin Inhibitors. Transplantation, 2009, 87, S1-S6.	0.5	45
27	Combined Liver-Kidney Transplants: Allosensitization and Recipient Outcomes. Transplantation, 2011, 91, 1286-1292.	0.5	45
28	QUANTITATIVE ASSESSMENT OF THE FIRST ACUTE REJECTION AS A PREDICTOR OF RENAL TRANSPLANT OUTCOME. Transplantation, 1999, 68, 1318-1324.	0.5	45
29	The Effect of 2-Gram Versus 1-Gram Concentration Controlled Mycophenolate Mofetil on Renal Transplant Outcomes Using Sirolimus-Based Calcineurin Inhibitor Drug-Free Immunosuppression. Transplantation, 2005, 79, 926-934.	0.5	44
30	CMV Viremia Is Associated With a Decreased Incidence of BKV Reactivation after Kidney and Kidney-Pancreas Transplantation. Transplantation, 2013, 96, 1097-1103.	0.5	40
31	Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation. BJU International, 2008, 101, 1415-1419.	1.3	39
32	The impact of surveillance and rapid reduction in immunosuppression to control BK virus-related graft injury in kidney transplantation. Transplant International, 2013, 26, 822-832.	0.8	39
33	Simultaneous vs. Sequential Laparoscopic Bilateral Native Nephrectomy and Renal Transplantation. Transplantation, 2005, 80, 1124-1127.	0.5	38
34	A Randomized, Open-Label Study of Sirolimus Versus Cyclosporine in Primary De Novo Renal Allograft Recipients. Transplantation, 2013, 95, 1233-1241.	0.5	38
35	Laparoscopic Donor Nephrectomy Gene Expression Profiling Reveals Upregulation of Stress and Ischemia Associated Genes Compared to Control Kidneys. Transplantation, 2005, 80, 1067-1071.	0.5	35
36	Dramatic secular changes in prognosis for kidney transplant candidates in the United States. American Journal of Transplantation, 2019, 19, 414-424.	2.6	35

#	Article	IF	CITATIONS
37	Shipping living donor kidneys and transplant recipient outcomes. American Journal of Transplantation, 2018, 18, 632-641.	2.6	33
38	Allotransplantation of Cryopreserved Parathyroid Tissue for Severe Hypocalcemia in a Renal Transplant Recipient. American Journal of Transplantation, 2010, 10, 2061-2065.	2.6	32
39	Emergency Department Visits after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 674-683.	2.2	31
40	Deconvoluting Post-Transplant Immunity: Cell Subset-Specific Mapping Reveals Pathways for Activation and Expansion of Memory T, Monocytes and B Cells. PLoS ONE, 2010, 5, e13358.	1.1	29
41	The Incorporation of an Advanced Donation Program Into Kidney Paired Exchange: Initial Experience of the National Kidney Registry. American Journal of Transplantation, 2015, 15, 2712-2717.	2.6	29
42	mTOR inhibition: the learning curve in kidney transplantation. Transplant International, 2010, 23, 447-460.	0.8	28
43	Patient and Kidney Allograft Survival with National Kidney Paired Donation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 228-237.	2.2	25
44	Glomerular Filtration Rate Slopes Have Significantly Improved Among Renal Transplants in the United States. Transplantation, 2010, 90, 1499-1505.	0.5	24
45	Clinical Outcomes Associated With Induction Regimens Among Retransplant Kidney Recipients in the United States. Transplantation, 2015, 99, 1165-1171.	0.5	24
46	Evaluation of Flagging Criteria of United States Kidney Transplant Center Performance. Transplantation, 2017, 101, 1373-1380.	0.5	22
47	Stone Disease in Living-Related Renal Donors: Long-Term Outcomes for Transplant Donors and Recipients. Journal of Endourology, 2013, 27, 1520-1524.	1.1	21
48	Renal Autotransplantation and Modified Pyelovesicostomy for Intractable Metabolic Stone Disease. Journal of Urology, 2011, 186, 1910-1915.	0.2	19
49	The Use of Kidneys with Small Renal Tumors for Transplantation: Who Is Taking the Risk?. American Journal of Transplantation, 2012, 12, 48-54.	2.6	19
50	Residential Area Life Expectancy: Association With Outcomes and Processes of Care for Patients With ESRD in the United States. American Journal of Kidney Diseases, 2018, 72, 19-29.	2.1	16
51	The Use of Percutaneous Transluminal Angioplasty for Renal Artery Stenosis in Patients with Generalized Atherosclerosis. Journal of Urology, 1982, 127, 1072-1075.	0.2	15
52	The Current Level of Involvement of Urological Trainees and Faculty in Clinical Kidney Transplantation in the United States and Canada. Journal of Urology, 1997, 157, 1223-1225.	0.2	13
53	First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. American Journal of Transplantation, 2014, 14, 1346-1355.	2.6	13
54	Motivations and outcomes of compatible living donor–recipient pairs in paired exchange. American Journal of Transplantation, 2022, 22, 266-273.	2.6	13

#	Article	IF	CITATIONS
55	Early graft losses in paired kidney exchange: Experience from 10 years of the National Kidney Registry. American Journal of Transplantation, 2020, 20, 1393-1401.	2.6	12
56	Ensuring the need is met: A 50-year simulation study of the National Kidney Registry's family voucher program. American Journal of Transplantation, 2021, 21, 1128-1137.	2.6	12
57	The Role of Laparoscopy-assisted Renal Autotransplantation in the Treatment of Primary Ureteral Tumor. Annals of Surgical Oncology, 2014, 21, 3691-3697.	0.7	11
58	Renal Transplantations in African Americans: A Single-center Experience of Outcomes and Innovations to Improve Access and Results. Urology, 2014, 84, 68-77.	0.5	10
59	Fibrin Glue Injections: A Minimally Invasive and Cost-Effective Treatment for Post–Renal Transplant Lymphoceles and Lymph Fistulas. American Journal of Transplantation, 2016, 16, 694-699.	2.6	10
60	mTOR Inhibition and Clinical Transplantation. Transplantation, 2018, 102, S17-S18.	0.5	10
61	Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet. Annals of Transplantation, 2013, 18, 31-35.	0.5	10
62	Post-Transplant Diabetes Mellitus. Drugs and Aging, 2006, 23, 781-793.	1.3	9
63	Contrasting patterns of viral load response in transplant recipients with <scp>BK</scp> polyomavirus <scp>DNA</scp> emia on leflunomide therapy. Clinical Transplantation, 2013, 27, E230-6.	0.8	9
64	Hidden Selection Bias Deriving From Donor Organ Characteristics Does Not Affect Performance Evaluations of Kidney Transplant Centers. Medical Care, 2010, 48, 907-914.	1.1	8
65	Patient Participation in Research Among Solid Organ Transplant Recipients in the United States. Transplantation, 2011, 91, 1424-1435.	0.5	8
66	Use of the donor bladder trigone to facilitate pediatric en bloc kidney transplantation. Pediatric Transplantation, 2011, 15, 53-57.	0.5	8
67	Treatment With Sirolimus Is Associated With Less Weight Gain After Kidney Transplantation. Transplantation, 2013, 96, 480-486.	0.5	8
68	"Do the Right Thing. It Will Gratify Some People and Astonish the Rest."-M. Twain. American Journal of Transplantation, 2016, 16, 1039-1040.	2.6	7
69	The benefit to waitlist patients in a national paired kidney exchange program: Exploring characteristics of chain end living donor transplants. American Journal of Transplantation, 2022, 22, 113-121.	2.6	7
70	Simultaneous Liver-Kidney Transplantation: What are Our Obligations to the Kidney Only Recipient?. Current Transplantation Reports, 2017, 4, 110-115.	0.9	6
71	Improved Cadaver Allograft Survival in Transfused Recipients who Remain Serologically Negative for Cytomegalovirus. Journal of Urology, 1982, 127, 644-647.	0.2	5
72	Genomics and proteomics in transplantation. Current Opinion in Organ Transplantation, 2005, 10, 191-197.	0.8	4

#	Article	lF	Citations
73	A Contemporary Analysis of Outcomes and Modifiable Risk Factors of Ethnic Disparities in Kidney Transplantation. Journal of the National Medical Association, 2019, 111, 202-209.	0.6	4
74	Ex-vivo partial nephrectomy after living donor nephrectomy: Surgical technique for expanding kidney donor pool. Urology Annals, 2017, 9, 107.	0.3	4
75	Disseminated adenoviral infection masquerading as lower urinary tract voiding dysfunction in a kidney transplant recipient. Clinical Nephrology, 2014, 82 (2014), 332-336.	0.4	4
76	Risk aversion in the use of complex kidneys in paired exchange programs: Opportunities for even more transplants?. American Journal of Transplantation, 2022, 22, 1893-1900.	2.6	4
77	Can the nephron be spared?. Kidney International, 2011, 79, 804-806.	2.6	3
78	The Pharmacokinetics and Pharmacodynamics of TOL101, a Murine IgM Anti-Human αβ TÂCell Receptor Antibody, in Renal Transplant Patients. Clinical Pharmacokinetics, 2014, 53, 649-657.	1.6	3
79	Presence of peripheral artery disease in renal transplant outcomes – Don't throw the baby out with the bath water. Vascular Medicine, 2017, 22, 231-233.	0.8	3
80	Ethical principles governing organ transplantation apply to paired exchange programs. American Journal of Transplantation, 2020, 20, 1756-1757.	2.6	3
81	USE OF A CADAVERIC DONOR AORTA FOR VASCULAR REPLACEMENT IN KIDNEY TRANSPLANTATION. Journal of Urology, 1999, 161, 909-910.	0.2	2
82	Calcineurin inhibitor free protocols in organ transplantation. Current Opinion in Organ Transplantation, 2004, 9, 383-388.	0.8	2
83	Risk factors for and management of sirolimus-associated pneumonitis in kidney transplant recipients. Nature Clinical Practice Nephrology, 2008, 4, 250-251.	2.0	2
84	Re: Tollefson et al.: Surgical Treatment of Renal Cell Carcinoma in the Immunocompromised Transplant Patient (Urology 2010;75:1373-1377). Urology, 2011, 77, 254-255.	0.5	2
85	Surgical Complications after Kidney Transplantation. , 2011, , 281-298.		2
86	Editorial Comment. Urology, 2009, 74, 68.	0.5	1
87	Another step in defining the role of mTOR inhibitors in kidney transplantation. Transplant International, 2010, 23, 1082-1083.	0.8	1
88	Re: Hajj et al. Prevalence of Renal Cell Carcinoma in Patients with Autosomal Dominant Polycystic Kidney Disease and Chronic Renal Failure (Urology 2010;74:631-634). Urology, 2010, 75, 752-753.	0.5	1
89	Implementation of a novel living-donor kidney transplant preoperative checklist within the electronic medical record: a pilot study. Patient Safety in Surgery, 2015, 9, 28.	1.1	1
90	Optimizing immunosuppression: who can do more with less?. Transplant International, 2016, 29, 20-22.	0.8	1

#	Article	IF	Citations
91	Response to: De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at 2 Years. American Journal of Transplantation, 2005, 5, 1169-1169.	2.6	0
92	2071 THE EVOLVING OUTCOMES OF KIDNEY TRANSPLANT RECIPIENTS OVER 70 YEARS OF AGE. Journal of Urology, 2010, 183, .	0.2	0
93	2072 SIROLIMUS ASSOCIATED ALTERATIONS IN SEX HORMONE PROFILES; IMPACT ON PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS AND ERECTILE FUNCTION AMONG ADULT MALE KIDNEY TRANSPLANT RECIPIENTS. Journal of Urology, 2010, 183, .	0.2	O
94	2070 LIVING DONOR RENAL TRANSPLANTATION OVERCOMES RACIAL DISPARITIES IN AFRICAN AMERICAN RECIPIENTS. Journal of Urology, 2010, 183, .	0.2	0
95	2248 THE USE OF SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) - MERCAPTUACETYLTRIGLYCINE (MAG 3) TO DETECT DIFFICULT TO DIAGNOSE URINARY FISTULAE AFTER KIDNEY TRANSPLANTATION. Journal of Urology, 2011, 185, .	0.2	O
96	2063 WHEN IS A ZERO MISMATCHED KIDNEY TRANSPLANT REALLY A ZERO MISMATCH?. Journal of Urology, 2011, 185, .	0.2	0
97	Immunosuppression without calcineurin inhibition: by ZEUS. Lancet, The, 2011, 377, 788-789.	6.3	O
98	4-P. Human Immunology, 2013, 74, 54.	1.2	0
99	V1726 EXPANDING THE KIDNEY ORGAN DONOR POOL AND REDUCING PATIENT WAIT LIST TIMES THROUGH UTILIZATION OF LIVING DONOR KIDNEYS WITH RENAL ANGIOMYOLIPOMAS. Journal of Urology, 2013, 189, .	0.2	0
100	Editorial Comment. Urology, 2013, 82, 1443.	0.5	0
101	MP3-20 RENAL AUTOTRANSPLANTATION: AN UNDERUTILIZED OPERATION FOR COMPLEX UPPER TRACT PATHOLOGY. Journal of Urology, 2014, 191, .	0.2	O
102	Re: The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. European Urology, 2016, 70, 699.	0.9	0
103	Retransplantation after nonadherenceâ€related kidney allograft failure – forgive or forget?. Transplant International, 2019, 32, 1241-1243.	0.8	O
104	Basic Principles of Immunology in Urology. , 2012, , 495-529.e5.		0
105	The Kidney in Nonrenal Solid Organ Transplantation: Liver and Heart. , 2015, , 173-183.		O
106	PD25-09 RISK FACTORS FOR TECHNICAL FAILURE OF RENAL AUTOTRANSPLANT: RESULTS OF 103 CASES FROM A SINGLE INSTITUTION. Journal of Urology, 2018, 199, .	0.2	0
107	PD54-02 ASSESSING THE EFFECT OF RENAL AUTOTRANSPLANT ON CHRONIC KIDNEY PAIN USING A VALIDATE PAIN QUESTIONNAIRE. Journal of Urology, 2019, 201, .	ID 0.2	0